Scientists hunt clues in blood to outsmart cancer drug resistance
NCT ID NCT05272423
Summary
This study aims to learn why cancers with a specific KRAS mutation become resistant to targeted drugs. Up to 500 adults in the US whose cancer has progressed on these drugs will provide a blood sample or share their existing test results. Researchers will analyze these samples to identify the genetic changes that cause resistance, which could help doctors choose better treatments in the future.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KRAS P.G12C are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.